GYKI-11679 is primarily utilized in research settings to study its effects on neurological processes. It acts as a selective non-competitive antagonist for AMPA receptors, a subtype of glutamate receptors, making it valuable for investigating the role of these receptors in conditions like epilepsy, neurodegenerative diseases, and stroke. Researchers use it to better understand the mechanisms of excitotoxicity and to explore potential therapeutic targets. Its application in experimental models helps in developing insights into brain function and pathology.